Hereditary Angioedema Market Research Reveals Path To $4.14 Billion By 2030

The hereditary angioedema market is positioned for substantial expansion in the coming years, driven by advances in treatment options and an increased focus on personalized healthcare. As rare disease therapies continue to evolve alongside enhanced genetic screening techniques, the market is set to experience significant growth and innovation through 2030.

Projected Growth and Market Size of the Hereditary Angioedema Market
The hereditary angioedema market is anticipated to reach $4.15 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.0%. This upward trajectory is primarily fueled by the development of new oral and subcutaneous therapies, increased investment in rare disease drug research, broader adoption of personalized medicine, expansion in genetic screening initiatives, and improvements in long-term disease management. Key trends expected to influence this growth phase include the wider use of targeted bradykinin therapies, an increased preference for prophylactic treatment plans, a stronger focus on early genetic diagnosis, the rise of home-based self-administration treatments, and a more patient-centered approach to care.

The hereditary angioedema market size has grown strongly in recent years. It will grow from $2.81 billion in 2025 to $3.04 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing clinical awareness of rare genetic disorders, availability of plasma-derived c1 esterase inhibitors, expansion of specialty treatment centers, improved diagnostic accuracy for hae, growing patient advocacy initiatives.

Download a free sample of the hereditary angioedema market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Driving the Hereditary Angioedema Market
Several major pharmaceutical and biotechnology firms play pivotal roles in the hereditary angioedema market, including Takeda Pharmaceutical Company Limited, CSL Limited, Sanofi S.A., Pharming Group N.V., BioCryst Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intellia Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Astria Therapeutics Inc., Pharvaris N.V., Adverum Biotechnologies Inc., ADARx Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Spark Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, and Alnylam Pharmaceuticals Inc.

A notable collaboration occurred in July 2023 when BioCryst Pharmaceuticals, Inc., a US-based biopharmaceutical company, joined forces with Er-Kim Pharmaceuticals to bring ORLADEYO (berotralstat) to the Turkish market. This partnership aims to improve patient access to ORLADEYO for hereditary angioedema in Turkey while expanding BioCryst's footprint in the global rare disease sector. Er-Kim Pharmaceuticals specializes in the development, manufacturing, and marketing of high-quality medications across multiple therapeutic fields within Turkey.

View the full hereditary angioedema market report:
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Trends Influencing the Hereditary Angioedema Industry
Innovation in treatment modalities is shaping the hereditary angioedema market, with companies focusing on oral plasma kallikrein inhibitors that offer more convenient and effective on-demand therapies. These inhibitors work by blocking plasma kallikrein to reduce excessive bradykinin production, a key factor in hereditary angioedema attacks. For example, in September 2024, KalVista Pharmaceuticals, Inc., based in the US, announced that the FDA accepted its new drug application (NDA) for sebetralstat. This investigational oral plasma kallikrein inhibitor is designed to treat HAE attacks on-demand in both adults and pediatric patients aged 12 and above. The FDA's acceptance of this NDA marks a significant milestone toward potential product approval and market launch.

Market Segmentation and Forecast for the Global Hereditary Angioedema Market
This report segments the hereditary angioedema market as follows:
1) By Type: Hereditary Angioedema Type I, Hereditary Angioedema Type II
2) By Treatment Type: Prophylaxis, On-demand
3) By Drug Class: C-1 Esterase Inhibitors, Bradykinin Receptor Antagonist, Kallikrein Inhibitors, Other Drug Classes
4) By Route of Administration: Subcutaneous, Intravenous, Oral
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Further breakdown includes:
- For Hereditary Angioedema Type I: distinguishing between C1-Inhibitor Deficiency and Low C1-Inhibitor Levels.
- For Hereditary Angioedema Type II: differentiation among Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, and Genetic Mutations in the SERPING1 Gene.

This detailed segmentation provides a comprehensive view of the market's structure and highlights areas for targeted growth and development through the forecast period.

Our 2026 market reports now offer broader strategic coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.